363 related articles for article (PubMed ID: 35335126)
1. Botanically-Derived Δ
Fitzpatrick JM; Hackett B; Costelloe L; Hind W; Downer EJ
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335126
[TBL] [Abstract][Full Text] [Related]
2. MyD88-dependent and -independent signalling via TLR3 and TLR4 are differentially modulated by Δ
Fitzpatrick JM; Minogue E; Curham L; Tyrrell H; Gavigan P; Hind W; Downer EJ
J Neuroimmunol; 2020 Jun; 343():577217. PubMed ID: 32244040
[TBL] [Abstract][Full Text] [Related]
3. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
4. Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
Al-Ghezi ZZ; Miranda K; Nagarkatti M; Nagarkatti PS
Front Immunol; 2019; 10():1921. PubMed ID: 31497013
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.
Kozela E; Pietr M; Juknat A; Rimmerman N; Levy R; Vogel Z
J Biol Chem; 2010 Jan; 285(3):1616-26. PubMed ID: 19910459
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids Alleviate the LPS-Induced Cytokine Storm via Attenuating NLRP3 Inflammasome Signaling and TYK2-Mediated STAT3 Signaling Pathways In Vitro.
Suryavanshi SV; Zaiachuk M; Pryimak N; Kovalchuk I; Kovalchuk O
Cells; 2022 Apr; 11(9):. PubMed ID: 35563697
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Elmes MW; Kaczocha M; Berger WT; Leung K; Ralph BP; Wang L; Sweeney JM; Miyauchi JT; Tsirka SE; Ojima I; Deutsch DG
J Biol Chem; 2015 Apr; 290(14):8711-21. PubMed ID: 25666611
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
9. Receptor-mediated effects of Δ
Preteroti MW; Traboulsi H; Greiss P; Lapohos O; Fonseca GJ; Eidelman DH; Baglole CJ
Immunol Cell Biol; 2023 Feb; 101(2):156-170. PubMed ID: 36510483
[TBL] [Abstract][Full Text] [Related]
10. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
[TBL] [Abstract][Full Text] [Related]
11. Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme.
Hindocha C; Freeman TP; Schafer G; Gardner C; Bloomfield MAP; Bramon E; Morgan CJA; Curran HV
Addict Biol; 2020 May; 25(3):e12762. PubMed ID: 31013550
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids Δ
Majdi F; Taheri F; Salehi P; Motaghinejad M; Safari S
Med Hypotheses; 2019 Dec; 133():109371. PubMed ID: 31465975
[TBL] [Abstract][Full Text] [Related]
13. Modulation of TLR3/TLR4 inflammatory signaling by the GABAB receptor agonist baclofen in glia and immune cells: relevance to therapeutic effects in multiple sclerosis.
Crowley T; Fitzpatrick JM; Kuijper T; Cryan JF; O'Toole O; O'Leary OF; Downer EJ
Front Cell Neurosci; 2015; 9():284. PubMed ID: 26283920
[TBL] [Abstract][Full Text] [Related]
14. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY; McKeage K; Scott LJ
Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
[TBL] [Abstract][Full Text] [Related]
15. Δ
Hodges RM; Chase KJ; Tripson MA; Bingham S; Woolley-Roberts M; Guy GW; Soderstrom K
Cannabis Cannabinoid Res; 2023 Oct; 8(5):790-801. PubMed ID: 36125410
[No Abstract] [Full Text] [Related]
16. TLR activation pathways in HIV-1-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic Changes and the Roles of Cannabinoid Receptors and PPARγ in Developmental Toxicities Following Exposure to Δ9-Tetrahydrocannabinol and Cannabidiol.
Pandelides Z; Aluru N; Thornton C; Watts HE; Willett KL
Toxicol Sci; 2021 Jul; 182(1):44-59. PubMed ID: 33892503
[TBL] [Abstract][Full Text] [Related]
18. Canine immune cells express high levels of CB
Brown C; Mitsch M; Blankenship K; Campbell C; Pelanne M; Sears J; Bell A; Olivier AK; Ross MK; Archer T; Kaplan BLF
Vet Immunol Immunopathol; 2023 Nov; 265():110667. PubMed ID: 37931433
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.
Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM
J Pharmacol Exp Ther; 2020 Jun; 373(3):416-428. PubMed ID: 32179573
[TBL] [Abstract][Full Text] [Related]
20. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
